IL132087A0 - Modified proteins which bind extracellular matrix components - Google Patents

Modified proteins which bind extracellular matrix components

Info

Publication number
IL132087A0
IL132087A0 IL13208798A IL13208798A IL132087A0 IL 132087 A0 IL132087 A0 IL 132087A0 IL 13208798 A IL13208798 A IL 13208798A IL 13208798 A IL13208798 A IL 13208798A IL 132087 A0 IL132087 A0 IL 132087A0
Authority
IL
Israel
Prior art keywords
extracellular matrix
matrix components
modified proteins
viral
bind extracellular
Prior art date
Application number
IL13208798A
Other languages
English (en)
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of IL132087A0 publication Critical patent/IL132087A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/857—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from blood coagulation or fibrinolysis factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
IL13208798A 1997-04-10 1998-04-08 Modified proteins which bind extracellular matrix components IL132087A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83722397A 1997-04-10 1997-04-10
PCT/US1998/006936 WO1998044938A1 (en) 1997-04-10 1998-04-08 Modified proteins which bind extracellular matrix components

Publications (1)

Publication Number Publication Date
IL132087A0 true IL132087A0 (en) 2001-03-19

Family

ID=25273860

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13208798A IL132087A0 (en) 1997-04-10 1998-04-08 Modified proteins which bind extracellular matrix components

Country Status (11)

Country Link
US (6) US6864082B2 (xx)
EP (2) EP0973538B1 (xx)
JP (3) JP2001523089A (xx)
AT (1) ATE388720T1 (xx)
AU (1) AU737727B2 (xx)
CA (1) CA2285937C (xx)
DE (1) DE69839243T2 (xx)
ES (1) ES2303726T3 (xx)
IL (1) IL132087A0 (xx)
NZ (1) NZ500006A (xx)
WO (1) WO1998044938A1 (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE388720T1 (de) * 1997-04-10 2008-03-15 Univ Southern California Sich an extrazelluläre matrixbestandteile anbindende modifizierte proteine
US6387663B1 (en) 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
DE60025830T2 (de) 1999-07-21 2006-11-02 University Of Southern California, Los Angeles Fusions-polypeptide zur gewebegeneration und wundheilung zur gezielten matrixanwendung
US20020064520A1 (en) * 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
US8163893B2 (en) * 2006-02-15 2012-04-24 The Regents Of The University Of Caifornia Pseudotyped retroviral vectors and methods of use thereof
IL149144A0 (en) * 1999-10-29 2002-11-10 Univ Southern California Modified viral surface proteins which bind to cells of tumor vasculature
AU2001259174A1 (en) * 2000-04-28 2001-11-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies
US7175658B1 (en) 2000-07-20 2007-02-13 Multi-Gene Vascular Systems Ltd. Artificial vascular grafts, their construction and use
HUP0300810A2 (hu) 2000-07-20 2003-08-28 M.G.V.S. Ltd. Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása
ES2186501B1 (es) * 2000-11-23 2006-05-16 Universidad De Malaga Factor de crecimiento fibroblastico basico con un dominio de union especifico a colegeno.
WO2002044394A2 (en) 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
WO2003087329A2 (en) * 2002-04-11 2003-10-23 University Of Southern California Targeted cytocidal virionoids for antiangiogenesis
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
EP1619951B1 (en) 2003-04-21 2011-06-22 Epeius Biotechnologies Corporation Methods and compositions for treating disorders
US20070178066A1 (en) * 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
CA2818691C (en) 2010-12-21 2021-08-03 Science Applications International Corporation Methods to identify actin or rdg peptide motifs in wound sites and compositions and methods for wound treatment
WO2012112690A2 (en) * 2011-02-16 2012-08-23 Fabius Biotechnology Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
AU2014236208B2 (en) 2013-03-14 2018-07-19 Genvivo, Inc. Thymidine kinase diagnostic assay for gene therapy applications
EP3712273A1 (en) 2016-04-08 2020-09-23 Krystal Biotech, LLC Compositions for the treatment of wounds, disorders, and diseases of the skin
CA3094345A1 (en) 2018-04-12 2019-10-17 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
US10786438B2 (en) 2018-04-27 2020-09-29 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
WO2020068862A1 (en) 2018-09-24 2020-04-02 Krystal Biotech, Inc. Compositions and methods for the treatment of netherton syndrome
WO2020163703A1 (en) 2019-02-08 2020-08-13 Krystal Biotech, Inc. Compositions and methods for delivering cftr polypeptides
US11779660B2 (en) 2021-04-02 2023-10-10 Krystal Biotech, Inc. Viral vectors for cancer therapy

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1038306A (zh) * 1988-03-21 1989-12-27 维吉恩公司 重组反转录病毒
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
JPH05503852A (ja) 1990-01-19 1993-06-24 アメリカ合衆国 新規なレトロウイルスベクター
WO1992006180A1 (en) 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells
CA2072581A1 (en) * 1990-10-25 1992-04-26 Clague Hodgson Method of gene transfer using retrotransposons
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
WO1993000103A1 (en) 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
CA2142325A1 (en) 1992-09-21 1994-03-31 William T. L. Lee Recombinant retroviral vector against felv and/or fiv
CA2145063A1 (en) * 1992-09-22 1994-03-31 Cambridge Genetics Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
JP3533219B2 (ja) 1992-11-09 2004-05-31 アメリカ合衆国 標的指向ベクター粒子
WO1994012626A1 (en) 1992-11-20 1994-06-09 University Of Medicine & Dentistry Of New Jersey Cell-type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins
EP0689601B1 (en) 1993-02-22 2006-10-04 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
WO1994027643A1 (en) 1993-06-01 1994-12-08 Targeted Genetics Corporation Envelope fusion vectors for use in gene delivery
JPH09500534A (ja) * 1993-07-22 1997-01-21 メルク エンド カンパニー インコーポレーテッド トランスジェニック動物でのヒトインターロイキン―１βの発現
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
CN1133616A (zh) 1993-10-22 1996-10-16 德克萨斯大学董事会 一种新的核有丝分裂磷蛋白：核分裂激素
US5643770A (en) * 1994-07-21 1997-07-01 Alexion Pharmaceuticals, Inc. Retroviral vector particles expressing complement inhibitor activity
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
CA2211993A1 (en) 1995-01-31 1996-08-08 The Rockefeller University Identification of dec, (dentritic and epithelial cells, 205 kda), a receptor with c-type lectin domains, nucleic acids encoding dec, and uses thereof
AU5320296A (en) * 1995-03-24 1996-10-16 Genetic Therapy, Inc. Modified viral envelope polypeptide
GB9506782D0 (en) * 1995-04-01 1995-05-24 British Biotech Pharm Retroviral vectors
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
ATE388720T1 (de) 1997-04-10 2008-03-15 Univ Southern California Sich an extrazelluläre matrixbestandteile anbindende modifizierte proteine
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
TWI293878B (en) 2000-06-30 2008-03-01 Taipei Veterans General Hospital A composition comprising a mevalonate-reducing compound for sensitizing cancer cells to cancer therapies and kits comprising said composition and an anti-cancer agent
IL154589A0 (en) 2000-08-25 2003-09-17 Aventis Pharma Inc Membrane penetrating peptides and uses thereof

Also Published As

Publication number Publication date
US20130331547A1 (en) 2013-12-12
EP2008664A3 (en) 2009-03-11
US8871734B2 (en) 2014-10-28
WO1998044938A1 (en) 1998-10-15
US7347998B2 (en) 2008-03-25
CA2285937A1 (en) 1998-10-15
US6864082B2 (en) 2005-03-08
US20110065179A1 (en) 2011-03-17
EP0973538B1 (en) 2008-03-12
ES2303726T3 (es) 2008-08-16
AU6890398A (en) 1998-10-30
US8530441B2 (en) 2013-09-10
EP2008664A2 (en) 2008-12-31
JP2008031178A (ja) 2008-02-14
AU737727B2 (en) 2001-08-30
DE69839243T2 (de) 2009-04-30
US20030118551A1 (en) 2003-06-26
DE69839243D1 (de) 2008-04-24
US8148509B2 (en) 2012-04-03
EP0973538A4 (en) 2001-09-19
ATE388720T1 (de) 2008-03-15
EP0973538A1 (en) 2000-01-26
JP2001523089A (ja) 2001-11-20
US20120276052A1 (en) 2012-11-01
US7820157B2 (en) 2010-10-26
CA2285937C (en) 2010-12-14
JP2011234740A (ja) 2011-11-24
US20050244376A1 (en) 2005-11-03
NZ500006A (en) 2001-09-28
US20080241905A1 (en) 2008-10-02
EP2008664B1 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
IL132087A0 (en) Modified proteins which bind extracellular matrix components
TR199900666T2 (xx) �nsan paratormonu ile ilgili peptidlere kar�� antikor.
DE60033293D1 (de) Neue b7-4 moleküle und deren verwendungen
DE60035517D1 (de) Gl50 moleküle, sowie verwendungen derselben
ATE378407T1 (de) Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
ATE308561T1 (de) Trail bindender rezeptor
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
CA2285667A1 (en) Viral vectors having chimeric envelope proteins containing the igg-binding domain of protein a
EP1009752A4 (en) NOVEL TANGO-77 PROTEIN FAMILY MOLECULES AND USES THEREOF
DE69836963D1 (de) PGC-1, EIN NEUARTIGER PPAR-gamma-KOAKTIVATOR AUS BRAUNEM FETTGEWEBE
MXPA02008239A (es) Gen humano de la esquizofrenia.
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
BR9710975A (pt) Genes de proteìna de adesão de superfìcie exposta de 120 kda imunodominante de ehrlichia chaffeensis
EP1005539A4 (en) IKK-ALPHA PROTEINS, NUCLEIC ACIDS AND METHOD
WO2000046236A3 (en) Novel rgs-containing molecules and uses thereof
EP1208196A4 (en) NEW SECRETINE FAMILY GPCR TYPE 15571 MOLECULE AND USES THEREOF
AUPM710194A0 (en) Virus vector
AU2003270010A8 (en) Transferrin fusion protein libraries
WO2001064876A3 (en) Human schizophrenia gene
WO1993025682A3 (en) Chimeric receptor polypeptides, human h13 proteins and uses thereof
WO2001073074A3 (en) 18806, a novel trypsin serine protease-like molecule and uses thereof
WO2001064894A3 (en) Human phospholipid scramblase-like molecules and uses thereof
AU2003222606A1 (en) Diagnosis of carcinoma using raigi polypeptides
NZ513915A (en) Chimeric proteins comprising 6 contiguous amino acids that bind to the GIT fused to a second protein, which may be a drug
AU2001288284A1 (en) 14189, a human kinase and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees